Biotech IPO Market Thaws: Eikon, Agomab, SpyGlass and Veradermics Lead Billion-Dollar Revival

The long-frozen window for biotechnology initial public offerings has been thrown wide open. In a definitive signal that risk appetite has returned to the life sciences sector, four emerging biopharma companies—Eikon Therapeutics, Agomab Therapeutics, SpyGlass Pharma, and Veradermics—successfully priced IPOs during the first week of February 2026. The flurry of listings generated nearly $1 billion in combined gross proceeds, marking the most significant week of capital formation for the industry in recent memory.

This resurgence is not merely a spike in volume but a test of investor selectivity. The successful debuts of these four companies, spanning oncology, immunology, ophthalmology, and dermatology, suggest that institutional investors are once again willing to deploy capital, provided the science is robust and the commercial pathway is clear.

Eikon Therapeutics Sets New High-Water Mark

The headline event of the week arrived with Eikon Therapeutics. The California-based oncology company listed on the Nasdaq with an upsized offering that raised $381 million, cementing its status as the largest biotech IPO since 2024.

Eikon priced 21.2 million shares at $18 apiece, the top end of its marketed $16 to $18 range. This was a clear vote of confidence from Wall Street, as the company had initially planned to sell only 17.6 million shares. The demand allowed Eikon to secure gross proceeds significantly higher than the $273.5 million in net proceeds it had originally targeted.

The company’s ability to command such a valuation highlights a renewed market willingness to back high-science platform plays. Eikon is capitalizing on Nobel Prize-winning super-resolution fluorescence microscopy to track protein dynamics in living cells, a sophisticated approach to drug discovery that has evidently resonated with public market investors.

The financing runway provided by this IPO is substantial. According to filings, the $381 million windfall will bankroll the clinical advancement of its oncology pipeline. The total raise could climb even higher, increasing by approximately $57.2 million, if underwriters exercise their 30-day option to purchase an additional 3.2 million shares. By surpassing the $318 million raised by Aktis Oncology in early January, Eikon has effectively reset the bar for what is possible in the 2026 market environment.

Agomab Therapeutics Brings European Innovation to NASDAQ

While Eikon anchored the week with sheer size, Belgian biotech Agomab Therapeutics demonstrated that US investors remain eager for high-quality European assets. Trading under the ticker “AGMB” on the Nasdaq, Agomab priced its offering at $16 per share, squarely in the middle of its projected $15 to $17 range.

The offering of 12.5 million shares generated $200 million in gross proceeds. Agomab, which specializes in fibrosis and tissue repair, represents a strategic bet on mechanism-driven immunology. The company plans to use the capital to fund a global Phase 2b study of ontunisertib (AGMB-129). This oral small molecule, an ALK5 inhibitor, has previously shown promise in targeting intestinal tissue in patients with fibrostenosing Crohn’s disease.

The funding is critical for Agomab’s strategy of positioning ontunisertib, the company’s lead candidate, as a combination therapy. The goal is to use the drug alongside existing Crohn’s treatments to halt the scarring process, a significant unmet need in the field.

The Agomab listing serves as a liquidity event for early backers and a validation of its M&A strategy, particularly its 2021 acquisition of Origo Biopharma, which brought ontunisertib into the pipeline. Should underwriters utilize their option to buy an additional 1.9 million shares, the company could add another $30 million to its balance sheet.

SpyGlass Pharma Validates the MedTech-Biotech Hybrid Model

Joining Agomab on the Nasdaq was SpyGlass Pharma, an eye-care company that bridges the gap between traditional drug development and medical devices. Trading under the ticker “SGP,” SpyGlass priced 9.4 million shares at $16 each to raise $150 million.

SpyGlass offers a distinct value proposition focused on compliance and long-acting delivery. Its lead product, the Bimatoprost Drug Pad-IOL System, is an intraocular lens capable of delivering the glaucoma drug bimatoprost for multiple years. By integrating drug delivery into a device implanted during routine cataract surgery, SpyGlass aims to eliminate the daily burden of eye drops for patients.

The successful pricing of this IPO indicates strong market support for “de-risked” technologies that reformulate approved drugs into novel delivery systems. The proceeds will fund two ongoing Phase 3 clinical trials, with capital also allocated for a potential commercial launch if the data proves positive.

The SpyGlass deal also includes a standard “greenshoe” option. If underwriters purchase the additional 1.4 million shares available to them, the gross proceeds would rise by approximately $22.5 million.

Veradermics Explodes on Debut with “Oral Rogaine” Pitch

If Eikon represented institutional prestige, Veradermics represented raw market enthusiasm. The Connecticut-based biotech, which is developing an oral formulation of minoxidil for hair regrowth, saw its stock price more than double on its first day of trading.

Listing on the New York Stock Exchange under the ticker “MANE,” Veradermics priced its upsized offering at $17 per share. The company sold just over 15 million shares to raise $256.3 million. The market reaction was immediate and fierce. On Wednesday, February 4, shares soared to close at $37.75, delivering a return of over 100% to IPO investors in a single session.

Veradermics is tapping into the massive lifestyle medicine market. While oral minoxidil is used off-label, it carries cardiovascular risks. Veradermics claims its proprietary formulation mitigates these side effects while maintaining efficacy, offering a cleaner alternative to messy topical treatments. The explosive trading debut suggests that generalist investors are hungry for biotech stories with easily understood commercial potential and large consumer addressable markets.

A Bifurcated but Healthy Market Recovery

The first week of February 2026 offers several key takeaways for the broader biopharma industry. First, the “mega-round” is back. Eikon’s $381 million raise proves that deep pockets are available for companies with pedigree management and differentiated platforms. The freeze that forced many companies to rely on insider extensions or reverse mergers appears to be thawing.

Second, the market is discriminating but diverse. Investors are not solely focused on one therapeutic area. The week’s winners spanned cancer (Eikon), gut health (Agomab), vision (SpyGlass), and aesthetics (Veradermics). This breadth indicates a healthy ecosystem where capital is allocated based on specific clinical merit rather than sector-wide hype.

Third, the “de-risking” premium remains real. While Eikon sold a discovery engine, SpyGlass and Veradermics sold late-stage assets based on well-understood pharmacology (bimatoprost and minoxidil). The massive pop in Veradermics stock specifically highlights a market preference for assets that are close to commercialization and carry lower biological risk.

As the industry moves deeper into 2026, the performance of these four classes of stock will likely serve as a barometer. If Eikon and Agomab can hold their valuations and Veradermics maintains its momentum, the backlog of private biotech companies waiting for an exit may finally begin to clear. For now, the message from Wall Street is unambiguous. The window is open.

Author

Richard Chau

Related Post

Prime

[Illustrations] Selective Capital, Targeted Deals, and a Tightened Public-Market Bar: How 2026 Is Shaping M&A and IPOs

2026-02-09

Ranking & Reports

Palantir Stock is Skyrocketing as its AI Tech Promises Big Gains

2025-02-05

Ranking & Reports

China’s Ascentage Snatches First Biotech IPO Price of 2025, Raking in $126M

2025-01-24